News & Analysis on Contract Research, Manufacturing & Clinical Trials
DCAT WEEK '17
BioVectra: North America’s market need
By Melissa Fassbender
- Last updated on
In 2015, BioVectra purchased a GMP API facility from Sepracor. It then began an 18-month refurbishing in 2016 that is expected to be completed in the third quarter of 2017.
In total, the company invested $30m, Marc Sauer, VP research and development said.
The facility itself offers 60,000 sq. ft. of manufacturing space, 40,000 liters for fermentation, and sits on six acres of property, “so there is potential for future expansion.”
“This is truly an investment in BioVectra’s core strength in process development and commercial manufacturing,” he explained, adding that microbial fermentation remains a vital technology for manufacturing biologics and complex small molecules
“The Contract GMP fermentation services market is fragmented,” Sauer explained.
“There is a true market need in North America,” he said adding, “everybody is looking for cost reduction.”